Charles Riv Labs Intl Inc Financials
Charles Riv Labs Intl Inc (CRL) reported $4.0B in revenue for fiscal year 2025, down 0.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash generation remains durable while reported earnings fade, revealing a business shaped more by non-cash charges than sales loss.
Across the last three years, revenue was nearly flat, but operating margin compressed from the mid-teens to0.6% , showing that the earnings problem is cost absorption, not a demand collapse. At the same time, free-cash-flow margin reached12.9% as depreciation and amortization rose to$403M ; lower receivables and inventory versus earlier years also helped cash hold up far better than GAAP profit.
The balance sheet still reflects an acquisition-built model: goodwill is
Total liabilities fell to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Charles Riv Labs Intl Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Charles Riv Labs Intl Inc has an operating margin of 0.6%, meaning the company retains $1 of operating profit per $100 of revenue. This results in a moderate score of 53/100, indicating healthy but not exceptional operating efficiency. This is down from 5.6% the prior year.
Charles Riv Labs Intl Inc's revenue declined 0.9% year-over-year, from $4.0B to $4.0B. This contraction results in a growth score of 27/100.
Charles Riv Labs Intl Inc has elevated debt relative to equity (D/E of 0.68), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 13/100, reflecting increased financial risk.
Charles Riv Labs Intl Inc's current ratio of 1.29 indicates adequate short-term liquidity, earning a score of 33/100. The company can meet its near-term obligations, though with limited headroom.
Charles Riv Labs Intl Inc converts 12.9% of revenue into free cash flow ($518.5M). This strong cash generation earns a score of 72/100.
Charles Riv Labs Intl Inc posts a -4.6% return on equity (ROE), meaning it loses $5 for every $100 of shareholders' equity. This results in a returns score of 46/100. This is down from 0.6% the prior year.
Charles Riv Labs Intl Inc scores 2.94, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($13.3B) relative to total liabilities ($3.9B). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Charles Riv Labs Intl Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Charles Riv Labs Intl Inc reported a net loss of $144.3M while generating $737.6M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Charles Riv Labs Intl Inc earns $0.24 in operating income for every $1 of interest expense ($25.2M vs $107.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Charles Riv Labs Intl Inc generated $4.0B in revenue in fiscal year 2025. This represents a decrease of 0.9% from the prior year.
Charles Riv Labs Intl Inc's EBITDA was $428.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 27.3% from the prior year.
Charles Riv Labs Intl Inc reported -$144.3M in net income in fiscal year 2025. This represents a decrease of 750.1% from the prior year.
Charles Riv Labs Intl Inc earned -$2.91 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Charles Riv Labs Intl Inc generated $518.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 3.4% from the prior year.
Charles Riv Labs Intl Inc held $213.8M in cash against $2.1B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Charles Riv Labs Intl Inc's operating margin was 0.6% in fiscal year 2025, reflecting core business profitability. This is down 5.0 percentage points from the prior year.
Charles Riv Labs Intl Inc's net profit margin was -3.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 4.1 percentage points from the prior year.
Charles Riv Labs Intl Inc's ROE was -4.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 5.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Charles Riv Labs Intl Inc spent $360.7M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 202.6% from the prior year.
Charles Riv Labs Intl Inc invested $219.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 5.9% from the prior year.
Not reported for fiscal year 2025.
CRL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0B | $4.0B-0.9% | $4.0B-1.9% | $4.1B+3.9% | $4.0B+12.3% | $3.5B+21.1% | $2.9B+11.5% | $2.6B+15.7% | $2.3B+22.0% | $1.9B+10.5% | $1.7B+23.3% | $1.4B+5.1% | $1.3B+11.3% | $1.2B+3.2% | $1.1B-1.1% | $1.1B |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $289.7M+4.6% | $277.0M+4.9% | $264.0M-0.9% | $266.4M-2.3% | $272.8M+5.8% | $257.7M-3.8% | $268.0M |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.6B+11.6% | $1.4B+27.8% | $1.1B+6.6% | $1.0B+15.5% | $892.8M+2.4% | $871.8M-0.3% | $874.7M |
| SG&A Expenses | $762.0M | $743.1M-1.1% | $751.0M+0.4% | $747.9M+12.4% | $665.1M+7.3% | $619.9M+17.2% | $528.9M+2.2% | $517.6M+16.6% | $443.9M+19.6% | $371.3M+1.8% | $364.7M+21.4% | $300.4M+11.7% | $269.0M+19.2% | $225.7M+8.4% | $208.2M+4.8% | $198.6M |
| Operating Income | $90.1M | $25.2M-88.9% | $227.3M-63.2% | $617.3M-5.2% | $651.0M+10.4% | $589.9M+36.3% | $432.7M+23.2% | $351.2M+6.0% | $331.4M+15.0% | $288.3M+21.4% | $237.6M+15.1% | $206.4M+16.2% | $177.7M+17.4% | $151.4M-8.7% | $165.8M-4.9% | $174.3M |
| Interest Expense | $106.3M | $107.0M-15.3% | $126.3M-7.6% | $136.7M+130.6% | $59.3M-19.8% | $73.9M-14.5% | $86.4M+42.0% | $60.9M-4.5% | $63.8M+114.2% | $29.8M+7.5% | $27.7M+83.8% | $15.1M+26.1% | $11.9M-43.0% | $21.0M-37.1% | $33.3M-21.7% | $42.6M |
| Income Tax | $52.6M | $42.7M-37.1% | $67.8M-32.8% | $100.9M-22.6% | $130.4M+59.2% | $81.9M+0.1% | $81.8M+63.5% | $50.0M-8.2% | $54.5M-68.2% | $171.4M+156.4% | $66.8M+54.0% | $43.4M-9.0% | $47.7M+44.8% | $32.9M+19.1% | $27.6M+61.2% | $17.1M |
| Net Income | -$238.5M | -$144.3M-750.1% | $22.2M-95.3% | $474.6M-2.4% | $486.2M+24.4% | $391.0M+7.3% | $364.3M+44.6% | $252.0M+11.3% | $226.4M+83.5% | $123.4M-20.3% | $154.8M+3.7% | $149.3M+17.8% | $126.7M+23.2% | $102.8M+5.1% | $97.9M-11.0% | $110.0M |
| EPS (Diluted) | — | -$2.91 | $0.20 | $9.22-2.7% | $9.48+24.7% | $7.60+5.6% | $7.20+42.0% | $5.07+9.7% | $4.62+81.9% | $2.54-21.4% | $3.23+3.2% | $3.13+17.7% | $2.66+25.5% | $2.12+5.5% | $2.01-6.1% | $2.14 |
Not reported in any period shown, so not listed: R&D Expenses.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CRL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.1B-5.2% | $7.5B-8.1% | $8.2B+7.8% | $7.6B+8.2% | $7.0B+27.9% | $5.5B+17.0% | $4.7B+21.7% | $3.9B+31.6% | $2.9B+8.0% | $2.7B+31.1% | $2.1B+10.6% | $1.9B+14.6% | $1.6B+2.9% | $1.6B+1.8% | $1.6B |
| Current Assets | $1.4B+3.1% | $1.4B-12.8% | $1.6B+11.8% | $1.4B+12.9% | $1.3B+6.1% | $1.2B+17.6% | $1.0B+13.8% | $897.8M+8.6% | $826.6M+25.9% | $656.8M+17.5% | $559.2M-3.5% | $579.3M+4.8% | $552.5M+13.9% | $485.3M+14.0% | $425.8M |
| Cash & Equivalents | $213.8M+9.8% | $194.6M-29.7% | $276.8M+18.3% | $233.9M-3.0% | $241.2M+5.6% | $228.4M-4.0% | $238.0M+21.8% | $195.4M+19.3% | $163.8M+39.2% | $117.6M-0.3% | $117.9M-26.3% | $160.0M+2.6% | $155.9M+42.2% | $109.7M+59.2% | $68.9M |
| Inventory | $299.1M+7.4% | $278.5M-26.7% | $380.3M+48.6% | $255.8M+28.5% | $199.1M+7.2% | $185.7M+15.6% | $160.7M+25.6% | $127.9M+11.3% | $115.0M+20.0% | $95.8M+2.2% | $93.7M+5.3% | $89.0M-0.4% | $89.4M+1.0% | $88.5M-4.8% | $93.0M |
| Accounts Receivable | $708.9M-1.7% | $720.9M-7.6% | $780.4M+3.7% | $752.4M+17.0% | $642.9M+4.1% | $617.7M+20.2% | $514.0M+8.8% | $472.2M+9.8% | $430.0M+18.1% | $364.1M+34.8% | $270.1M+4.7% | $258.0M+16.9% | $220.6M+8.7% | $203.0M+9.8% | $184.8M |
| Goodwill | $2.8B-2.9% | $2.8B-8.0% | $3.1B+8.6% | $2.8B+5.1% | $2.7B+49.9% | $1.8B+17.4% | $1.5B+23.5% | $1.2B+54.9% | $804.9M+2.2% | $787.5M+79.5% | $438.8M+36.7% | $321.1M+39.2% | $230.7M+10.6% | $208.6M+5.6% | $197.6M |
| Total Liabilities | $3.9B-2.4% | $4.0B-11.4% | $4.5B-0.9% | $4.6B+3.3% | $4.4B+32.4% | $3.3B+10.6% | $3.0B+20.2% | $2.5B+34.9% | $1.9B+0.4% | $1.9B+42.6% | $1.3B+11.7% | $1.2B+20.5% | $968.1M-1.5% | $983.1M-4.6% | $1.0B |
| Current Liabilities | $1.1B+12.7% | $994.1M-5.8% | $1.1B-3.3% | $1.1B+5.7% | $1.0B+23.0% | $839.8M+18.2% | $710.2M+27.2% | $558.2M+20.4% | $463.5M+7.9% | $429.6M+37.8% | $311.8M+5.8% | $294.7M+19.3% | $247.0M-27.8% | $342.2M+57.9% | $216.8M |
| Long-Term Debt | $2.1B-4.6% | $2.2B-15.4% | $2.6B-2.2% | $2.7B+1.7% | $2.7B+38.0% | $1.9B+4.3% | $1.8B+13.7% | $1.6B+49.0% | $1.1B-8.1% | $1.2B+44.7% | $821.0M+13.7% | $722.0M+12.5% | $641.8M+21.8% | $527.1M-25.0% | $703.2M |
| Total Equity | $3.2B-8.6% | $3.5B-3.8% | $3.6B+20.9% | $3.0B+17.4% | $2.5B+19.9% | $2.1B+29.4% | $1.6B+24.1% | $1.3B+26.1% | $1.0B+24.9% | $836.8M+14.1% | $733.1M+9.1% | $672.2M+4.9% | $641.0M+6.7% | $600.8M+14.3% | $525.6M |
| Retained Earnings | $1.4B-23.4% | $1.8B-4.0% | $1.9B+31.7% | $1.4B+46.1% | $980.8M+56.8% | $625.4M+123.1% | $280.3M+565.9% | $42.1M-85.4% | $288.7M+74.6% | $165.3M+1468.6% | $10.5M+107.6% | -$138.8M+47.7% | -$265.5M+27.9% | -$368.3M+20.9% | -$465.6M |
CRL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $582.1M | $737.6M+0.4% | $734.6M+7.4% | $683.9M+10.4% | $619.6M-18.6% | $760.8M+39.2% | $546.6M+13.6% | $480.9M+9.0% | $441.1M+38.7% | $318.1M+0.4% | $316.9M+3.3% | $306.8M+21.7% | $252.1M+20.6% | $209.0M+0.5% | $208.0M+0.6% | $206.8M |
| Capital Expenditures | $211.5M | $219.2M-5.9% | $233.0M-26.9% | $318.5M-1.9% | $324.7M+41.9% | $228.8M+37.4% | $166.6M+18.5% | $140.5M+0.3% | $140.1M+69.9% | $82.4M+49.1% | $55.3M-12.6% | $63.3M+11.1% | $56.9M+45.4% | $39.2M-17.6% | $47.5M-3.3% | $49.1M |
| Free Cash Flow | $370.6M | $518.5M+3.4% | $501.6M+37.3% | $365.4M+23.9% | $294.9M-44.6% | $532.0M+40.0% | $380.0M+11.6% | $340.4M+13.1% | $301.1M+27.8% | $235.6M-9.9% | $261.6M+7.4% | $243.6M+24.8% | $195.2M+14.9% | $169.9M+5.9% | $160.5M+1.8% | $157.7M |
| Investing Cash Flow | -$506.3M | -$209.3M+14.6% | -$245.1M+56.5% | -$563.2M+7.4% | -$607.9M+57.7% | -$1.4B-139.0% | -$601.5M+11.7% | -$681.5M+28.6% | -$955.0M-1215.7% | -$72.6M+89.5% | -$692.7M | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$21.4M | -$536.7M+2.6% | -$550.9M-544.2% | -$85.5M-101.7% | -$42.4M-106.3% | $672.6M+1323.5% | $47.2M-79.6% | $231.9M-58.4% | $558.1M+367.7% | -$208.5M-154.8% | $380.8M | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $324.1M | $360.7M+202.6% | $119.2M+393.4% | $24.2M-37.5% | $38.7M-5.1% | $40.7M+69.8% | $24.0M+32.6% | $18.1M+30.6% | $13.8M-87.0% | $106.9M+771.5% | $12.3M-89.6% | $117.5M-3.7% | $122.0M-26.5% | $165.9M+158.5% | $64.2M-77.4% | $283.8M |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CRL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 84.4%+0.9pp | 83.5%+2.9pp | 80.6%+1.2pp | 79.5%+2.9pp | 76.6%-0.6pp | 77.2%+0.6pp | 76.5% |
| Operating Margin | 0.6%-5.0pp | 5.6%-9.3pp | 14.9%-1.4pp | 16.4%-0.3pp | 16.7%+1.9pp | 14.8%+1.4pp | 13.4%-1.2pp | 14.6%-0.9pp | 15.5%+1.4pp | 14.1%-1.0pp | 15.1%+1.5pp | 13.7%+0.7pp | 13.0%-1.7pp | 14.7%-0.6pp | 15.3% |
| Net Margin | -3.6%-4.1pp | 0.5%-10.9pp | 11.5%-0.7pp | 12.2%+1.2pp | 11.0%-1.4pp | 12.5%+2.8pp | 9.6%-0.4pp | 10.0%+3.4pp | 6.6%-2.6pp | 9.2%-1.8pp | 10.9%+1.2pp | 9.8%+0.9pp | 8.8%+0.2pp | 8.7%-1.0pp | 9.6% |
| Return on Equity | -4.6%-5.2pp | 0.6%-12.6pp | 13.2%-3.1pp | 16.3%+0.9pp | 15.4%-1.8pp | 17.2%+1.8pp | 15.4%-1.8pp | 17.2%+5.4pp | 11.8%-6.7pp | 18.5%-1.9pp | 20.4%+1.5pp | 18.9%+2.8pp | 16.0%-0.3pp | 16.3%-4.6pp | 20.9% |
| Return on Assets | -2.0%-2.3pp | 0.3%-5.5pp | 5.8%-0.6pp | 6.4%+0.8pp | 5.6%-1.1pp | 6.6%+1.3pp | 5.4%-0.5pp | 5.9%+1.7pp | 4.2%-1.5pp | 5.7%-1.5pp | 7.2%+0.5pp | 6.8%+0.5pp | 6.3%+0.1pp | 6.2%-0.9pp | 7.1% |
| Current Ratio | 1.29-0.1x | 1.41-0.1x | 1.52+0.2x | 1.32+0.1x | 1.23-0.2x | 1.430.0x | 1.44-0.2x | 1.61-0.2x | 1.78+0.3x | 1.53-0.3x | 1.79-0.2x | 1.97-0.3x | 2.24+0.8x | 1.42-0.5x | 1.96 |
| Debt-to-Equity | 0.680.0x | 0.65-0.1x | 0.74-0.2x | 0.91-0.1x | 1.05+0.1x | 0.91-0.2x | 1.13-0.1x | 1.23+0.2x | 1.04-0.4x | 1.42+0.3x | 1.120.0x | 1.07+0.1x | 1.00+0.1x | 0.88-0.5x | 1.34 |
| FCF Margin | 12.9%+0.5pp | 12.4%+3.5pp | 8.8%+1.4pp | 7.4%-7.6pp | 15.0%+2.0pp | 13.0%0.0pp | 13.0%-0.3pp | 13.3%+0.6pp | 12.7%-2.9pp | 15.6%-2.3pp | 17.9%+2.8pp | 15.0%+0.5pp | 14.6%+0.4pp | 14.2%+0.4pp | 13.8% |
Similar Companies
Where Charles Riv Labs Intl Inc Ranks
Frequently Asked Questions
What is Charles Riv Labs Intl Inc's annual revenue?
Charles Riv Labs Intl Inc (CRL) reported $4.0B in total revenue for fiscal year 2025. This represents a -0.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Charles Riv Labs Intl Inc's revenue growing?
Charles Riv Labs Intl Inc (CRL) revenue declined by 0.9% year-over-year, from $4.0B to $4.0B in fiscal year 2025.
Is Charles Riv Labs Intl Inc profitable?
No, Charles Riv Labs Intl Inc (CRL) reported a net income of -$144.3M in fiscal year 2025, with a net profit margin of -3.6%.
What is Charles Riv Labs Intl Inc's EBITDA?
Charles Riv Labs Intl Inc (CRL) had EBITDA of $428.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Charles Riv Labs Intl Inc have?
As of fiscal year 2025, Charles Riv Labs Intl Inc (CRL) had $213.8M in cash and equivalents against $2.1B in long-term debt.
What is Charles Riv Labs Intl Inc's operating margin?
Charles Riv Labs Intl Inc (CRL) had an operating margin of 0.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Charles Riv Labs Intl Inc's net profit margin?
Charles Riv Labs Intl Inc (CRL) had a net profit margin of -3.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Charles Riv Labs Intl Inc's return on equity (ROE)?
Charles Riv Labs Intl Inc (CRL) has a return on equity of -4.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Charles Riv Labs Intl Inc's free cash flow?
Charles Riv Labs Intl Inc (CRL) generated $518.5M in free cash flow during fiscal year 2025. This represents a 3.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Charles Riv Labs Intl Inc's operating cash flow?
Charles Riv Labs Intl Inc (CRL) generated $737.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Charles Riv Labs Intl Inc's total assets?
Charles Riv Labs Intl Inc (CRL) had $7.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Charles Riv Labs Intl Inc's capital expenditures?
Charles Riv Labs Intl Inc (CRL) invested $219.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Charles Riv Labs Intl Inc's current ratio?
Charles Riv Labs Intl Inc (CRL) had a current ratio of 1.29 as of fiscal year 2025, which is considered adequate.
What is Charles Riv Labs Intl Inc's debt-to-equity ratio?
Charles Riv Labs Intl Inc (CRL) had a debt-to-equity ratio of 0.68 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Charles Riv Labs Intl Inc's return on assets (ROA)?
Charles Riv Labs Intl Inc (CRL) had a return on assets of -2.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Charles Riv Labs Intl Inc's Altman Z-Score?
Charles Riv Labs Intl Inc (CRL) has an Altman Z-Score of 2.94, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Charles Riv Labs Intl Inc's Piotroski F-Score?
Charles Riv Labs Intl Inc (CRL) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Charles Riv Labs Intl Inc's earnings high quality?
Charles Riv Labs Intl Inc (CRL) reported a net loss of $144.3M while generating $737.6M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Charles Riv Labs Intl Inc cover its interest payments?
Charles Riv Labs Intl Inc (CRL) has an interest coverage ratio of 0.24x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Charles Riv Labs Intl Inc?
Charles Riv Labs Intl Inc (CRL) scores 41 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.